Empagliflozin Treatment in Kidney Transplant Recipients (NCT06013865)
An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)
🩺 Plain-English Summary (8th-Grade Level)
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.
Who can join: Review the eligibility criteria below.
Location: Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
Age range: 19 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
- Iowa City VA Health Care System, Iowa City, IA — Iowa City, Iowa
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA — Pittsburgh, Pennsylvania
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (205) 999-7362
Email: roslyn.mannon@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant
- Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study — Pittsburgh, Pennsylvania
- Pro-active Genetic Testing in Kidney Transplant Patients — Scottsdale, Arizona
- Dapagliflozin in Living-Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Phenotype Guided Vasoactive Medication During Kidney Transplantation — Los Angeles, California
- GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial — Livingston, New Jersey
- Letermovir for R+ Study — Madison, Wisconsin
Explore by condition: All Kidney Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.